Conflicting Data In Review Of New GnRH Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Writers of journal article say enough data exists to warrant more study of increased cardiovascular risks found in prostate cancer patients taking the drugs.
You may also be interested in...
FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver
FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.
FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver
FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.
FDA Clears Drugs With Post-Market Safety Questions Faster Than It Re-labels
FDA's "1early communication" program for alerting the public about potential drug safety issues produces a clean bill of health for products about 40 percent of the time, according to an analysis by "The Pink Sheet." And those positive decisions come much quicker than labeling changes the program has produced for drugs where genuine concerns have emerged